课题基金基金详情
天然免疫系统IL-33-ILC2信号轴启动早期2型免疫反应在创伤/休克肺血管通透性增高中的作用及机制
结题报告
批准号:
81670445
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
徐竞
依托单位:
学科分类:
H0218.微循环与休克
结题年份:
2020
批准年份:
2016
项目状态:
已结题
项目参与者:
吴惠玲、臧家涛、刘建仓、彭小勇、张紫森、赵洪梁
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
血管通透性增高是严重创伤/休克后的重要病理生理改变,但机制远未阐明。基于天然免疫系统早期激活是导致后期复杂临床表现重要原因的最新认识,根据前期研究发现创伤/休克后肺IL-33-ILC2信号轴活化,启动早期2型免疫反应,以及文献报道2型细胞因子IL-5可调节血管通透性,推测天然免疫系统IL-33-ILC2信号轴活化可能促进创伤/休克后的血管通透性增高。本研究拟采用C57BL/6小鼠、以及骨髓重建获得的ILC2 KO小鼠,复制严重创伤/休克模型,采用流式细胞、免疫荧光、离体细胞和整体动物水平的血管通透性检测等技术,观察:1)IL-33-ILC2信号轴在严重创伤/休克后肺血管通透性增高中的作用;2)IL-33-ILC2轴启动早期2型免疫反应后,是否通过促进VEGF和MMP-9表达,降低VE-Cad,开放内皮细胞间途径,导致血管通透性增高。以期从新的角度阐明严重创伤/休克血管通透性增高的启动机制。
英文摘要
Vascular hyperpermeability is an important pathological change after severe trauma/shock, while its mechanism is still unclear. Based on the the latest opinion that the early activated innate immune system could lead to the later complicated clinical trajectories; and our preliminary study which showed the interleukin-33 (IL-33)- type II innate lymphoid cells (ILC2) signal axis of the innate immune system was activated and triggered the early type 2 immune response after severe trauma/shock; as well as the previous researches which reported the regulatory effect of type 2 cytokine IL-5 on vascular permeability, so we presumed that the IL-33-ILC2 signal axis of the innate immune system could be activated and contribute to the vascular hyperpermeability after severe trauma/shock. To verify the hypothesis, the C57BL/6 mice and ILC2 KO mice set up by bone marrow reconstituting were used to make the severe trauma/shock model, and the flow cytometry, immunofluorescence, vascular permeability detection technique in vivo and in vitro were adopted to observe: 1) Role of IL-33-ILC2 signal axis in the vascular hyperpermeability in lung after severe trauma/shock; 2) If IL-33-ILC2 signal axis activation and the early type 2 immune response lead to the vascular hyperpermeability after severe trauma/shock by promoting the expression of vascular endothelial growth factor (VEGF) and activation of matrix metalloproteinase-9 (MMP-9), decreasing the expression of vascular- endothelial cadherin (VE-Cad), and opening the paracellular pathway. With this research, we hope to illuminate the startup mechanism of vascular hyperpermeability after severe trauma/shock with a new view.
血管通透性增高是严重创伤/休克后的重要病理改变,但机制远未阐明。基于天然免疫系统早期激活可导致后期复杂临床表现的最新认识,根据前期研究发现严重创伤/休克后肺IL-33-ILC2信号轴活化,启动早期2型免疫反应,以及文献报道IL-5对血管通透性有调节作用,推测天然免疫系统IL-33-ILC2信号轴活化可能促进严重创伤/休克后血管通透性增高。本研究采用骨髓重建获得ILC2 KO小鼠,采用流式细胞、免疫荧光、离体细胞和整体动物血管通透性检测等技术,发现:1)严重创伤/休克后C57BL/6小鼠肺中IL-33-ILC2信号轴活化,出现2型免疫反应上调,IL-33、IL-5以及ILC2水平均显著增高,而双肺湿重增加,肺伊文思蓝通透率显著增加,均在6h尤为明显。 IL-33中和抗体可显著抑制创伤/休克后增高的肺ILC2百分比和增高的IL-5水平、以及增高的肺伊文思蓝通透率;IL-5中和抗体也可显著抑制创伤/休克后增高的肺伊文思蓝通透率。肺HE染色显示创伤/休克6h后小鼠出现显著的肺损伤,并可由IL-33中和抗体、以及IL-5中和抗体缓解;ILC2 KO 可显著降低创伤后肺IL-5水平,减轻肺伊文斯兰通透率和HE染色显示的肺损伤。2)严重创伤/休克后VEGF、MMP-9的蛋白表达显著增高,与肺血管通透性呈正相关,VE-Cad的蛋白表达显著降低,与肺血管通透性呈负相关,VEGF受体抑制剂SU5614可显著抑制创伤/休克后增高的肺MMP-9和VE-Cad蛋白表达,缓解肺血管通透性增高,IL-33和IL-5中和抗体均可显著降低创伤/休克6h增高的肺VEGF、MMP-9蛋白表达,增高创伤/休克6h降低的肺VE-Cad蛋白表达;ILC2 WT小鼠中,创伤/休克6h肺VEGF、MMP-9蛋白表达显著增高,VE-Cad蛋白表达显著降低,在ILC2 KO小鼠,与ILC2 KO正常对照组相比,创伤/休克6h肺VEGF、MMP-9、 VE-Cad蛋白表达均无显著变化。体外细胞实验进一步证实IL-33-ILC2信号轴启动2型免疫反应后,通过调节VEGF 和MMP-9,降低VE-Cad,导致严重创伤/休克后肺血管通透性增高。因此,本研究发现IL-33-ILC2信号轴启动早期2型免疫反应参与了严重创伤/休克肺血管通透性增高,其机制与VEGF和MMP-9参与的VE-Cad蛋白表达调控有关.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model.
严重创伤后肺部反应中 IL33 介导的 ILC2 激活和中性粒细胞 IL5 产生:从人类队列到小鼠创伤模型的反向翻译研究
DOI:10.1371/journal.pmed.1002365
发表时间:2017-07
期刊:PLoS medicine
影响因子:15.8
作者:Xu J;Guardado J;Hoffman R;Xu H;Namas R;Vodovotz Y;Xu L;Ramadan M;Brown J;Turnquist HR;Billiar TR
通讯作者:Billiar TR
可变多聚腺苷酸化(APA)介导mRNA转录后调节参与浆液性卵巢癌铂耐药形成及其m6A协同调节机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    徐竞
  • 依托单位:
N6-甲基腺嘌呤修饰协同调节靶基因mRNA可变多聚腺苷酸化导致浆液性卵巢癌铂耐药的机制研究
  • 批准号:
    --
  • 项目类别:
    省市级项目
  • 资助金额:
    0.0万元
  • 批准年份:
    2021
  • 负责人:
    徐竞
  • 依托单位:
国内基金
海外基金